Quibim, a Valencia-based HealthTech company innovating the use of imaging biomarkers for precision medicine, announced today the close of its €47.9 million Series A financing in order establish US presence.

The financing was led by Asabys (through its fund Sabadell Asabys II) and Buenavista Equity Partners (through the BHG I fund, created in partnership with Columbus Venture Partners), and joined by GoHub Ventures and UI Investissement as new investors. It was also joined by current investors, Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund’s early growth fund), Tony Fadell’s Build Collective, and individual investor Dr. Jonathan Milner, founder of Abcam plc.

“Quibim’s mission is to turn imaging into a catalyst for precision health, and we are deeply grateful to both our new and current investors for their support,” said Dr Ángel Alberich-Bayarri, CEO and Co-founder of Quibim. “Our global expansion into the U.S. is a critical milestone as we work with pharmaceutical leaders and healthcare providers to unlock the power of imaging to revolutionise diagnostics  and improve patient outcomes.”

Founded in 2012 by Dr Ángel Alberich-Bayarri and Luis Martí Bonmatí, Quibim is dedicated to the mission of unlocking a complete, non-invasive understanding of every tissue point in the human body, at any moment in time. To achieve this, the company develops foundational AI models applied to imaging that extract actionable insights from MRI, CT, and PET scans. These insights enable precise characterisation of phenotypes and prediction of outcomes in areas such as oncology, immunology, neurology and metabolic disorders.

Quibim says this is the pathway toward achieving human digital twins, dynamic models that not only reflect and allow health monitoring but also enhance patient stratification, improve the success rates of drug development programs, and enable treatment testing before application.

Today, the company is building digital twins at the organ and lesion level, exemplified by solutions like QP-Brain, QP-Prostate, and QP-Liver.

However, as the volume of whole-body scans and related imaging data continues to grow in the coming years, Quibim aims for their models to eventually analyse the entire body.

With over 170 installations worldwide, including in Mass General Brigham and Stanford, and regulatory clearances across the US, EU, UK, Quibim’s technology looks to bridgethe gap between research, clinical practice, and drug development.

Last year, Philips announced a global partnership with Quibim to integrate its AI models into MR scanners, while the company also secured strategic alliances with leading biopharma giants such as Merck KGaA and Novartis.

“Asabys is thrilled to support Quibim in transforming the imaging diagnostics space,” said Guillem Masferrer, Partner at Asabys Partners. “Their ability to combine AI with imaging biomarker discovery addresses critical unmet needs in​ oncology, neurology, and beyond. We are confident that Quibim’s innovative solutions will have a profound impact on global healthcare.”

Quibim’s product portfolio includes:

• QP-Prostate®: the company’s flagship product is designed to enhance prostate cancer detection through an industry-leading AI-powered lesion detection.
•  QP-Brain®: AI-based early-stage neurological disease quantification software for quantification of early brain atrophy and lesions.
• QP-Liver®: automated AI tool for MR diagnosis of diffuse liver diseases through accurate quantification of tissue fat and iron levels.
•  QP-Insights®: A platform to manage, store and analyse multi-omics data in clinical trials and real-world data studies. According to Quibim, QP-Insights is the platform managing the largest imaging datasets in the world, accounting for more than 100 million medical images.

With the series A financing, Quibim will establish a strong U.S. presence, building on its success in Europe, through strategic collaborations with hospitals and pharmaceutical companies.

“Quibim’s technology exemplifies the next wave of precision medicine,” said José Mesa, Partner at Columbus and Buenavista’s representative on the Board. “Their impressive track record with global pharmaceutical partnerships, including partnerships with companies such as Merck KGaA and Philips, exemplify Quibim’s role in transforming imaging data into valuable predictions for clinical trials and treatment planning. We expect that as Quibim develops its pipeline of companion diagnostic tools, we will see tremendous momentum for its technology and products.”

“The foundational research done by Quibim’s team has not only informed industry standards, but also led to the company pioneering an approach to combining radiomics and deep learning that is now a standard of its own,” said Pierre Socha, Partner at Amadeus Capital Partners. “This platform approach was novel at the time of our first investment and proved to be the right strategy for rapid scale-up.”